Physician
Encompass Family and Internal Medicine Group INC
Encompass Family and Internal Medicine Group INC was paid $33K by Medicaid between Jan 2018 and Nov 2024, across 35 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 91% of everything it billed.
33Billing provider infoENCOMPASS FAMILY AND INTERNAL MEDICINE GROUP INC
LA MESA, CA 91942
LA MESA, CA 91942
33aNPI1033449640assigned 01/04/2010
33bProvider typeGeriatric Medicine (Family Medicine) Physician
28Total paid$33K
24GClaims11,933
24DCodes billed35
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Geriatric Medicine (Family Medicine) Physician providers in California
Rank by total paid#30 of 80
Median peer was paid$8K
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 765 | $5K | |
| 2019 | 1,301 | $9K | |
| 2020 | 6,184 | $6K | |
| 2021 | 2,098 | $5K | |
| 2022 | 513 | $5K | |
| 2023 | 470 | $2K | |
| 2024incomplete | 602 | $636.48 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 91% | 3,092 | 2,493 | $30K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 5.1% | 2,893 | 2,135 | $2K |
| 99490 | Ccm add 20min | 2.2% | 52 | 52 | $724.96 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 612 | 447 | $123.87 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 263 | 227 | $59.20 |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 43 | 40 | $51.48 |
| 82670 | <1% | 172 | 135 | $41.91 | |
| 82627 | <1% | 153 | 120 | $33.36 | |
| 83001 | <1% | 168 | 132 | $27.87 | |
| 80061 | Lipid panel | <1% | 307 | 266 | $26.80 |
| 84403 | <1% | 86 | 66 | $25.82 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 198 | 163 | $25.20 |
23 more codes
| 82533 | <1% | 153 | $24.45 | |
| 82607 | <1% | 197 | $22.62 | |
| 82746 | <1% | 158 | $22.05 | |
| 84270 | <1% | 170 | $21.74 | |
| 84144 | <1% | 170 | $20.86 | |
| 82728 | <1% | 159 | $20.46 | |
| 84146 | <1% | 126 | $19.38 | |
| 83002 | <1% | 168 | $18.52 | |
| 80053 | Comprehensive metabolic panel | <1% | 340 | $15.84 |
| 84480 | <1% | 141 | $14.18 | |
| 86141 | <1% | 153 | $12.96 | |
| 83525 | <1% | 154 | $11.44 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 221 | $9.72 |
| 84439 | <1% | 169 | $9.02 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 205 | $7.78 |
| 83735 | <1% | 167 | $6.70 | |
| 83540 | <1% | 157 | $6.48 | |
| 84100 | <1% | 151 | $4.74 | |
| 84550 | <1% | 153 | $4.52 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 455 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 85 | $0.00 |
| 84153 | 0% | 19 | $0.00 | |
| 83090 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAJVARDI, ROBERT (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Birdrock | San Diego, CA | $3.16M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.